Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME-PRAXOL: Pramipexole as adjuvant treatment for anhedonia in depression
2024-512495-35-00Phase 3Completed
- Sponsor
- Region Skåne
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD), bipolar disorder (BD) and persistent depressive disorder (PDD) comparing Pramipexole arm with Placebo arm (2 arms). Primary endpoint: Snaith-Hamilton Pleasure Scale (SHAPS-C) total score. Started Apr 2024; status: completed.
02
Drugs
pramipexole
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)persistent depressive disorder (PDD)
Beyond the preview
Go deeper on 2024-512495-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512495-35-00.